robert e. bristow, md, mba professor and director division of gynecologic oncology university of...
TRANSCRIPT
![Page 1: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/1.jpg)
Robert E. Bristow, MD, MBAProfessor and Director
Division of Gynecologic OncologyUniversity of California, Irvine – Medical Center
Update on Ovarian Cancer
![Page 2: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/2.jpg)
Ovarian Cancer Center
Mission:•To provide exemplary and holistic clinical care to patients with ovarian cancer.•To enhance community awareness of ovarian cancer regarding the importance of early diagnosis and the benefits of centralized expert care.•To advance the science of the prevention and treatment of ovarian cancer in a meaningful way.
Discover ▪ Teach ▪ Heal
![Page 3: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/3.jpg)
Gynecologic OncologyFaculty
Discover ▪ Teach ▪ Heal
![Page 4: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/4.jpg)
Ovarian Cancer Center• Clinical Services - coordination of multidisciplinary care - prevention, early detection, cancer survivorship - surgery and regional therapeutics - chemotherapy and clinical trials - ancillary services• Community Outreach and Education - web-based platform - virtual support group survivor network - conferences - international visiting scholar program• Research and Discovery - molecular biology and translational science - healthcare outcomes
Discover ▪ Teach ▪ Heal
![Page 5: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/5.jpg)
Ann’s Clinic
High-risk patients
- genetic counseling & testing
- surveillance programs
- cancer prophylaxis
Cancer survivors
- programmatic plan
- psycho-social wellness
- management of treatment toxicities
Discover ▪ Teach ▪ Heal
Screening, Early Detection, Cancer Survivorship
![Page 6: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/6.jpg)
Discover ▪ Teach ▪ Heal
Peritoneal Surface Malignancies
Disease confined to peritoneal cavity for
much of natural history
Generally amenable to surgical resection
Positive survival impact of chemotherapy
- varies by disease site
Discover ▪ Teach ▪ Heal
![Page 7: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/7.jpg)
Sigmoid Tumor
Left Ovary
Right OvaryUterus
Bladder Tumor
Radical Surgery for Ovarian Cancer
Discover ▪ Teach ▪ Heal
![Page 8: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/8.jpg)
Culdesac Tumor
Distal SigmoidCervix
Uterus
Bladder Tumor
Radical Surgery for Ovarian Cancer
Discover ▪ Teach ▪ Heal
![Page 9: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/9.jpg)
RectosigmoidColon
Vaginal Cuff
Radical Surgery for Ovarian Cancer
Discover ▪ Teach ▪ Heal
![Page 10: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/10.jpg)
Development of Intra-Peritoneal (IP) Chemotherapy
• 1950’s: First use of intraperitoneal chemotherapy for malignant ascites
• 1968: Long-term peritoneal access device• 1978: Demonstration of slow peritoneal
clearance of some drugs• 1984: Feasibility of intermittent large volume
intraperitoneal therapy• 1996: First report of a survival benefit for IP
vs. IV chemotherapy in advanced ovarian cancer
Discover ▪ Teach ▪ Heal
![Page 11: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/11.jpg)
Armstrong DK et al. NEJM 2006; 354:34.
Discover ▪ Teach ▪ Heal
![Page 12: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/12.jpg)
Armstrong DK et al. NEJM 2006; 354: 34.
PFS: 18.3 vs 23.8 months OS: 49.7 vs 66.9 months
Discover ▪ Teach ▪ Heal
![Page 13: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/13.jpg)
12 14
24
37
52
57.466.9
0
20
40
60
80
Mo
nth
s
1975 1983 1986 1996 1998 2003 2006
IP Rx IP RxAlkeranAlkeran CisplatinCisplatin PaclitaxelPaclitaxel
(Optimal)(Optimal)
The ‘Evolution’ of Treatment forAdvanced Ovarian Cancer and Effect on Survival
Surgical & Chemotherapy Improvements
(Suboptimal)
Discover ▪ Teach ▪ Heal
![Page 14: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/14.jpg)
Discover ▪ Teach ▪ Heal
![Page 15: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/15.jpg)
IP Therapy
Discover ▪ Teach ▪ Heal
![Page 16: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/16.jpg)
IP Therapy
Discover ▪ Teach ▪ Heal
![Page 17: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/17.jpg)
IP Therapy
Discover ▪ Teach ▪ Heal
![Page 18: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/18.jpg)
Discover ▪ Teach ▪ Heal
IP Therapy
![Page 19: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/19.jpg)
Study Chemotherapy Residual Median Survival
GOG152 IV-CDDP/IV-Taxol >1cm 36 months
GOG172 IV-CDDP/IV-Taxol <1cm 50 months
IP-CDDP/IV+IP-Taxol <1cm 67 months
Primary Cytoreductive Surgery
Contemporary Survival Outcomes
0.1–1.0cm 39 monthsno gross 78 months
0.1–1.0cm 53 monthsno gross 127 months
Rose PG et al. N Eng J Med 2004; 351: 2489.Armstrong DK et al. N Eng J Med 2006; 354: 34.
Discover ▪ Teach ▪ Heal
![Page 20: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/20.jpg)
Discover ▪ Teach ▪ Heal
Hyperthermia and Neoplasia
Directly cytotoxic to cancer cells
- disrupts microtubule system
- induces primary protein damage
- promotes vascular stasis
Synergistic with some chemotherapy agents
Heat is…
Knox 1991, Stellar 1998
Discover ▪ Teach ▪ Heal
![Page 21: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/21.jpg)
Discover ▪ Teach ▪ Heal
HIPEC Schematic
Discover ▪ Teach ▪ Heal
![Page 22: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/22.jpg)
Discover ▪ Teach ▪ Heal
HIPEC Techniques
Open (colisuem)
Closed
Discover ▪ Teach ▪ Heal
![Page 23: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/23.jpg)
Discover ▪ Teach ▪ Heal
Role of HIPEC in Ovarian Cancer
Melis A et al. Bull Cancer 2011, doi 21659062.
Retrospective study design (1995-2005)
Advanced ovarian cancer (n=43)
Up-front HIPEC cisplatin + IV chemotherapy
Morbidity – 13.9%; mortality – 2.3%
Median OS = 53 months
- complete initial resection = 131 months
Median PFS = 39 months
Discover ▪ Teach ▪ Heal
![Page 24: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/24.jpg)
Burger RA et al. NEJM 2011; 365: 2473.
Discover ▪ Teach ▪ Heal
![Page 25: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/25.jpg)
PFS: +3.8 month maintenance Rx OS: no significant effect
Discover ▪ Teach ▪ Heal
Burger RA et al. NEJM 2011; 365: 2473.
![Page 26: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/26.jpg)
Fertility Preservation• Ovarian cancer - conservative surgery - young patients - early stage disease, atypical tumor types - chemotherapy with ovarian suppression
Discover ▪ Teach ▪ Heal
![Page 27: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/27.jpg)
Robotic Surgery
● daVinci surgical platform - patient-side robot
- vision cart
- robotic master console
AdvantagesImproved visualization
Finer instrument control and dexterityErgonomic design
Autonomous surgical environment
Discover ▪ Teach ▪ Heal
![Page 28: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/28.jpg)
da Vinci® – Robotic Surgery Technology
Discover ▪ Teach ▪ Heal
![Page 29: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/29.jpg)
Clinical Trials
• Ovarian cancer
- intraperitoneal chemotherapy / HIPEC
- molecular profiling
- quality of life / cancer survivorship
- developmental therapeutics / biologic agents
Discover ▪ Teach ▪ Heal
Research and Discovery
![Page 30: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/30.jpg)
Research and Discovery
• PhD recruitment underway
• Collaborative effort
• Genetic screening and early detection
• Molecular basis of disease
- characteristics of long-term survivors
- circumventing chemo-resistance
Discover ▪ Teach ▪ Heal
QOH Ovarian Cancer Research Laboratory
![Page 31: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/31.jpg)
Research and Discovery
• Surgical techniques
• Advanced imaging techniques / onco-imaging
• Clinical trials of new chemotherapeutic agents
• Biological therapies
• Public health applications
Discover ▪ Teach ▪ Heal
![Page 32: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/32.jpg)
Modern Approach to Cancer Therapeutics
Patient Metabolism
Pathways Analysis
Mutations
Genes Upregulated
Genes Downregulated
Research and Discovery
Discover ▪ Teach ▪ Heal
![Page 33: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/33.jpg)
OVA1 Qualitative serum test – 5 immunoassays - Apolipoprotein A - Transthyretin
- 2 Microglobulin - Transferrin
- CA125 II
Single numerical result: 0 - 10 FDA approved September 2009 Ovarian mass, > 18y/o, planned surgery Triage tool for surgical decision-making Not a screening or independent diagnostic test
Category Low Risk High RiskPremenopausal <5.0 ≥5.0Postmenopausal <4.4 ≥4.4
Discover ▪ Teach ▪ Heal
![Page 34: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/34.jpg)
Performance Preoperative Assessment
Assessment + OVA1
Sensitivity % 75 96
Specificity % 79 35
NPV % 87 95
PPV % 62 40
Subjects OVA1 CA125-II
All cancers (n=161) 92.5% 68.9%
All epithelial ovarian cancers (n=96) 99.0% 82.3%
Early stage EOC (n=41) 97.6% 65.9%
Premenopausal women w/ early stage EOC (n=14)
92.9% 35.7%
OVA1
Ueland F. et al. Int Gyn Cancer Soc Annual Meeting, 2010, Prague.
Sensitivity vs CA125
Overall Performance
Discover ▪ Teach ▪ Heal
![Page 35: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/35.jpg)
Disparities in Epithelial Ovarian CancerQuality of Care and Survival According to
Race and Socioeconomic Status:a Study of 47,160 Patients fromthe National Cancer Data Base
Robert E. Bristowa, Matthew A. Powellb, Noor Al-Hammadic, Ling Chenc,J. Phillip Millerc, Phillip Y. Rolandd, David G. Mutchb, William A. Clibye
aDivision of Gynecologic Oncology, Department of Obstetrics and GynecologyUniversity of California, Irvine School of Medicine
bDivision of Gynecologic Oncology, Department of Obstetrics and GynecologycDepartment of Biostatistics
Washington University in St. Louis School of MedicinedGynecologic Oncology, Department of Gynecology and Obstetrics
Saint Francis Francis Hospital and Medical CentereDivision of Gynecologic Surgery, Department of Obstetrics and Gynecology
Mayo Clinic
Discover ▪ Teach ▪ Heal
![Page 36: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/36.jpg)
Adherence to NCCN GuidelinesRace
35.6%
43.9%
51.3%
61.5%56.4%
65.6%
*p<0.0001* * *
Discover ▪ Teach ▪ Heal
![Page 37: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/37.jpg)
Adherence to NCCN GuidelinesPayer
* *p<0.0001**
Discover ▪ Teach ▪ Heal
![Page 38: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/38.jpg)
5-year Overall SurvivalAdherent White 41.4%Non-adherent White 37.8%Adherent African-American 33.3%Non-adherent African-American 22.5%p<0.0001
N=47,160
Adherent/Non-Adherent Care by Race
Discover ▪ Teach ▪ Heal
![Page 39: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/39.jpg)
Outreach and EducationPublic Community
- Education and Awareness
- Virtual support network
Resource for Professionals
- Education and Awareness
- Expedited referral system
- Partnering in patient care
Discover ▪ Teach ▪ Heal
![Page 40: Robert E. Bristow, MD, MBA Professor and Director Division of Gynecologic Oncology University of California, Irvine – Medical Center Update on Ovarian](https://reader036.vdocuments.us/reader036/viewer/2022062620/551a09d3550346a4248b47d9/html5/thumbnails/40.jpg)
Discover ▪ Teach ▪ Heal
Thank you!